Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

NCT05680129 is registered in ClinicalTrials.gov with Hangzhou Sciwind Biosciences Co., Ltd. as lead sponsor.

NCT NCT05680129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2023
Completion date
October 12, 2024
Enrollment
623 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm, type 2 diabetes mellitus